2-hydroxyglutaric acid

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 1586 references associated with 2-hydroxyglutaric acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2-hydroxyglutaric acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-hydroxyglutaric acid

MeSH term MeSH ID Detail
Phenylketonurias D010661 7 associated lipids
Canavan Disease D017825 2 associated lipids
Metabolic Diseases D008659 12 associated lipids
Tyrosinemias D020176 2 associated lipids
Hyperoxaluria D006959 3 associated lipids
Total 5

PubChem Associated disorders and diseases

PubChem Biomolecular Interactions and Pathways

NCBI Entrez Crosslinks

All references with 2-hydroxyglutaric acid

Download all related citations
Per page 10 20 50 100 | Total 448
Authors Title Published Journal PubMed Link
Wang P et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. 2015 Cell Rep pmid:26686626
Tateishi K et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. 2015 Cancer Cell pmid:26678339
Churchill H et al. Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma. 2015 Int J Clin Exp Pathol pmid:26617922
Li F et al. NADP(+)-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. 2015 Mol. Cell pmid:26585387
Lombardi G et al. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. 2015 Oncologist pmid:25862748
Pellegatta S et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. 2015 Acta Neuropathol Commun pmid:25849072
Ma S et al. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. 2015 Oncotarget pmid:25825982
Oizel K et al. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. 2015 Cell Death Dis pmid:25811801
Keum YS and Choi BY Isocitrate dehydrogenase mutations: new opportunities for translational research. 2015 BMB Rep pmid:25787993
Shi X et al. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish. 2015 Blood pmid:25778530
Rzem R et al. A mouse model of L-2-hydroxyglutaric aciduria, a disorder of metabolite repair. 2015 PLoS ONE pmid:25763823
Hirata M et al. Mutant IDH is sufficient to initiate enchondromatosis in mice. 2015 Proc. Natl. Acad. Sci. U.S.A. pmid:25730874
Charitou P et al. FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression. 2015 EMBO Rep. pmid:25648147
Chan SM et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. 2015 Nat. Med. pmid:25599133
Fan J et al. Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. 2015 ACS Chem. Biol. pmid:25406093
Reitman ZJ et al. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. 2015 Blood pmid:25398939
Patay Z et al. Successive distinct high-grade gliomas in L-2-hydroxyglutaric aciduria. 2015 J. Inherit. Metab. Dis. pmid:25338511
Wen H et al. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. 2015 J. Neurochem. pmid:25251602
Natsumeda M et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. 2014 Acta Neuropathol Commun pmid:25376594
Chittaranjan S et al. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. 2014 Oncotarget pmid:25277207
Liu Z et al. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. 2014 J. Med. Chem. pmid:25271760
Shim EH et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. 2014 Cancer Discov pmid:25182153
Saha SK et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. 2014 Nature pmid:25043045
Pope WB Intraoperative mass spectrometry of tumor metabolites. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:25028494
Reitman ZJ et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. 2014 J. Biol. Chem. pmid:24986863
Santagata S et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:24982150
Kato Kaneko M et al. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. 2014 Cancer Sci. pmid:24898068
Fathi AT et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. 2014 Oncologist pmid:24760710
Elhammali A et al. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. 2014 Cancer Discov pmid:24740997
Tarhonskaya H et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. 2014 Nat Commun pmid:24594748
Akbay EA et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. 2014 Genes Dev. pmid:24589777
Pusch S et al. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. 2014 Acta Neuropathol Commun pmid:24529257
Menendez JA et al. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. 2014 Cell Cycle pmid:24526120
Borger DR et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. 2014 Clin. Cancer Res. pmid:24478380
Işıkay S et al. A child with L-2 hydroxyglutaric aciduria presenting with dilated cardiomyopathy: coincidence or a new syndrome? 2014 Anadolu Kardiyol Derg pmid:24382499
Terunuma A et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. 2014 J. Clin. Invest. pmid:24316975
Gilbert MR et al. Autophagy and oxidative stress in gliomas with IDH1 mutations. 2014 Acta Neuropathol. pmid:24150401
Navis AC et al. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. 2013 Acta Neuropathol Commun pmid:24252742
Wang JH et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. 2013 Proc. Natl. Acad. Sci. U.S.A. pmid:24082129
Lu C et al. Induction of sarcomas by mutant IDH2. 2013 Genes Dev. pmid:24065766
Chaumeil MM et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. 2013 Nat Commun pmid:24019001
McKenney AS and Levine RL Isocitrate dehydrogenase mutations in leukemia. 2013 J. Clin. Invest. pmid:23999441
Andronesi OC et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. 2013 J. Clin. Invest. pmid:23999439
Guilhamon P et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. 2013 Nat Commun pmid:23863747
Cairns RA and Mak TW Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. 2013 Cancer Discov pmid:23796461
DiNardo CD et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. 2013 Blood pmid:23641016
Losman JA and Kaelin WG What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. 2013 Genes Dev. pmid:23630074
Ward PS et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. 2013 J. Biol. Chem. pmid:23264629
Jin G et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. 2013 Cancer Res. pmid:23204232
Pollyea DA et al. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. 2013 Leuk. Lymphoma pmid:22680765